Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples

AIDS

Volumn 14, Issue 9, 2000, Pages 1203-1210

  Hertogs, Kurt ^a   Bloor, Stuart ^b   Kemp, Sharon D ^b   Van Den Eynde, Christel ^a   Alcorn, Timothy M ^d   Pauwels, Rudi ^a   Van Houtte, Margriet ^a   Staszewski, Schlomo ^c   Miller, Veronica ^c   Larder, Brendan A ^b  

^a Virco BVBA   (Belgium)

^b Virco UK Ltd   (United Kingdom)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

Cross resistance; Genotypic evaluation; Mutations; Phenotypic drug resistance; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS LOAD;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, MICROBIAL; EUROPE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; PHENOTYPE; UNITED STATES; VIRAL LOAD;

EID: 0033921617     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200006160-00018     Document Type: Article

References (28)

1. 1. Greene WC. The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med. 1991, 324:308-317.
2. 2. De Bouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses, 1992, 8:153-164.
3. 3. Harrigan PR, Hertogs K, Verbiest W, et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir therapy in a community setting. AIDS 1999, 13:1863-1871.
4. 4. Patick AK, Zhang M, Hertogs K, et al. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 57].
5. 5. Zolopa AR, Shafer RW, Warlord A, Montoya JG, Katzenstein D, Merigan TC. Predictors of antiviral response to saquinavir/ ritonavir therapy in a clinical cohort who have failed prior protease inhibitors: a comparison of clinical characteristics, antiretroviral drug history and HIV genotype. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 54].
6. 6. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antivir News 1997, 5: 129-142.
7. 7. Zhang YM, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and its Gag substrate cleavage sites. J Virol 1997, 71:6662-6670.
8. 8. Ives KJ, Jacobsen H, Galpin SA, et al. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J Antimicrob Chemother 1997, 39:771-779.
9. 9. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
10. 10. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
11. 11. Condra JH, Holder DJ, Shleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996, 70:8270-8276.
12. 12. Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996, 40:292-297.
13. 13. Boden D, Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 1998, 42:2775-2783.
14. 14. De Pasquale MP, Murphy R, Gulick R, et al. Mutations selected in HIV plasma RNA during 141W94 therapy. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 406a].
15. 15. Hertogs K, de Béthune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
16. 16. Pauwels R, Hertogs K, Kemp S, et al. Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 51].
17. 17. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280: 78-86.
18. 18. Kellam P, Larder B. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994, 38:23-30.
19. 19. Vingerhoets J, Bloor S, Michiels L, et al. The accuracy and reproducibility of high throughput genotypic and phenotypic HIV-1 resistance testing under EN45001 and CLIA accreditation labels. Third International Workshop on HIV Drug Resistance and Treatment Strategies. San Diego, June 1999 [abstract 77].
20. 20. Zolopa AR, Hertogs K, Shafer R, et al. A comparison of phenotypic, genotypic and clinical/treatment history predictors of virological response to saquinavir/ritonavir salvage therapy in a clinic-based cohort. Third International Workshop on HIV Drug Resistance and Treatment Strategies. San Diego, June 1999 [abstract 68].
21. 21. Hertogs K. De Vroey V, Van den Eynde C, et al. Common, rare and new genotypic and/or phenotypic HIV-1 resistance profiles observed in routine clinical practice: a survey of over 5000 isolates. Third International Workshop on HIV Drug Resistance and Treatment Strategies. San Diego, June 1999 [abstract 108].
22. 22. Hertogs K, Patick A, Schel P, et al. Phenotypic resistance testing (PR-RT-Antivirogram® ) of HIV-1 clinical isolates confirms the unique and different resistance pathway of nelfinavir. Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection. Hamburg, October 1997 [abstract 906].
23. 23. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998, 42: 2637-2644.
24. 24. Rhone SA, Hogg RS, Yip B, et al. The antiviral effect of rilonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS 1998, 12:619-624.
25. 25. Moyle, G. The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. Exp. Opin. Invest. Drugs 1998, 7:413-426.
26. 26. Shafer, RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998, 128:906-911.
27. 27. Söclerbärg K, Sitbon G, Sönnerborg A. Detection of drug resistance mutations in HIV-1 patients with early viral rebound during an on-going combination therapy programme. Third International Workshop on HIV Drug Resistance and Treatment Strategies. San Diego, June 1999 [abstract 117].
28. 28. Race E, Ferchal F, Dam E, et al. Selection of HIV-1 variants with wide cross-resistance to reverse transcriptase inhibitors during low-level escape to first-line dual nucleoside therapy. Third International Workshop on HIV Drug Resistance and Treatment Strategies. San Diego, June 1999 [abstract 118].